Obstet Gynecol. 2012 Mar;119(3):690-1. doi: 10.1097/AOG.0b013e31824e1327.
In light of the recent increased incidence of pertussis in the United States, in 2011, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices approved recommendations for the use of the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) for pregnant women. Furthermore, the committee updated Tdap recommendations for special situations during pregnancy and for persons in contact with infants. The revised guidelines, which are based on a review of data on Tdap safety, immunogenicity, and barriers to receipt of Tdap, are designed to facilitate the use of Tdap to reduce the burden of disease and risk of transmission to infants. There is no evidence of adverse fetal effects from the vaccination of pregnant women with an inactivated virus, bacterial vaccine, or toxoid, and these should be administered if indicated. The American College of Obstetricians and Gynecologists' Committee on Obstetric Practice supports the revised recommendations on the administration of Tdap during pregnancy.
鉴于美国百日咳发病率最近有所上升，2011 年，疾病预防控制中心免疫实践咨询委员会批准了孕妇使用破伤风类毒素、白喉类毒素和无细胞百日咳疫苗（Tdap）的建议。此外，该委员会还更新了 Tdap 在怀孕期间特殊情况下以及与婴儿接触者的建议。修订后的指南是基于对 Tdap 安全性、免疫原性和获得 Tdap 的障碍的数据进行审查而制定的，旨在促进使用 Tdap 来减轻疾病负担和降低向婴儿传播的风险。接种孕妇使用的灭活病毒、细菌疫苗或类毒素不会对胎儿产生不良影响，如果有需要，应予以接种。美国妇产科医师学会产科实践委员会支持修订后的 Tdap 在怀孕期间使用的建议。
